Aardvark Therapeutics, Inc

AARDNASDAQ · Pharmaceutical Preparations

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

21.9M

on 2026-06-30, from 4.07M on 2024-12-31 10-Q ↗

a raise that quarter, at its price

Newest

$400.0M

S-3 of 2026-03-23. 1 prospectus supplement filed under it since. S-3 ↗

$150.0M

Piper Sandler, agreement of 2026-04-03. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗

Warrants

The 10-Q filed 2026-08-11 is not read yet.

Cash

4.3 quarters

$73.9M on 2026-06-30 ÷ $17.4M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
Date	What	Shares	Price	Gross	Filing
2025-02-13	Public offering	not read	$16.00	not read	424B4 ↗